Journal
LEUKEMIA & LYMPHOMA
Volume 56, Issue 3, Pages 615-621Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428194.2014.924117
Keywords
Multiple myeloma; bisphosphonates; mortality; comparative effectiveness research
Categories
Funding
- Barnes Jewish Hospital Foundation
- [NHLBI/5K12HL087107]
- [NCI/KM1CA156708]
- [NHLBI/U54 HL112303]
Ask authors/readers for more resources
Zoledronic acid and pamidronate are the two bisphosphonates approved in the United States to reduce multiple myeloma skeletal complications. Little prior evidence exists comparing survival outcomes between the two. We evaluated the incidence of skeletal-related events and overall survival in patients with myeloma treated with zoledronic acid versus pamidronate using a cohort of 1018 United States veterans. At a median follow-up of 26.9 months, patients receiving zoledronic acid had a 22% reduction in risk of death compared to pamidronate (hazard ratio 0.78; 95% confidence interval, 0.67-0.92). The benefit persisted after controlling for potential confounders. Adjusted Cox modeling with inverse probability weighting and propensity score matching supported these findings. Zoledronic acid was also associated with a 25% decrease in skeletal-related events. Zoledronic acid is associated with increased overall survival and decreased skeletal-related events compared to pamidronate in patients with multiple myeloma and should become the preferred bisphosphonate.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available